Sun Pharmaceutical Industries Limited today announced that its wholly-owned Japanese subsidiary
has launched ILUMYA Subcutaneous Injection 100 mg Syringe (Nonproprietary name: tildrakizumab
(genetical recombination), “ILUMYA”) in Japan for the treatment of plaque psoriasis in adult patients who
have an inadequate response to conventional therapies.

ILUMYA is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of
IL23 and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of
proinflammatory cytokines and chemokines.

Junichi Nakamichi, Country Head, Sun Pharma Japan, said, “ILUMYA is Sun Pharma’s first innovative
drug to be launched in the Japanese market. We are pleased to introduce a new, safe and effective
treatment option for plaque psoriasis to doctors and patients in our country. This is an important
milestone for SunPharma as we expand our product portfolio in Japan.”